Iovance Biotherapeutics
Logotype for Iovance Biotherapeutics Inc

Iovance Biotherapeutics (IOVA) investor relations material

Iovance Biotherapeutics TD Cowen 46th Annual Health Care Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Iovance Biotherapeutics Inc
TD Cowen 46th Annual Health Care Conference summary2 Mar, 2026

Financial and operational performance

  • Achieved 30% quarterly revenue growth and a 50% gross margin in Q4 2025, with full-year revenue of $264 million, meeting guidance.

  • Operational improvements and cost optimization extended cash runway into Q3 2027.

  • All manufacturing for AMTAGVI is now internal, enabling better cost control and economies of scale.

  • Proleukin contributed 17% of annual revenue, with most use tied to AMTAGVI treatments.

  • Revenue guidance will be provided after more commercial data is available, potentially before the Q1 call.

Commercial strategy and market expansion

  • AMTAGVI adoption is accelerating, supported by expanding academic and community treatment centers.

  • Growth in 2026 will come from both deeper penetration and network expansion of authorized treatment centers (ATCs).

  • Initiatives focus on making patient access easier and increasing early treatment uptake.

  • Community center engagement is a key driver for broader reach and revenue growth.

  • Proleukin sales are expected to stabilize, with AMTAGVI as the primary growth driver.

Pipeline development and clinical milestones

  • Lifileucel demonstrated a 31% response rate and near 20-month median overall survival in heavily pretreated melanoma patients.

  • Higher response rates observed in real-world studies, especially with earlier AMTAGVI use.

  • Non-small cell lung cancer program targets a market seven times larger than melanoma, with Fast Track designation and potential launch in H2 2027.

  • Early data in soft tissue sarcomas showed a 50% response rate, with plans for a rapid, single-arm registrational trial.

  • Next-generation TIL therapies (IOV-4001, IOV-5001, IOV-3001) are advancing, aiming to address broader solid tumor indications.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Iovance Biotherapeutics earnings date

Logotype for Iovance Biotherapeutics Inc
Barclays 28th Annual Global Healthcare Conference11 Mar, 2026
Iovance Biotherapeutics
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Iovance Biotherapeutics earnings date

Logotype for Iovance Biotherapeutics Inc
Barclays 28th Annual Global Healthcare Conference11 Mar, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Iovance Biotherapeutics Inc is a biotechnology company focused on developing cell-based immunotherapies for the treatment of cancer. The company specializes in tumor-infiltrating lymphocyte (TIL) therapies, which involve harnessing and enhancing a patient's immune cells to target and destroy cancer cells. Iovance’s research primarily targets solid tumors, aiming to offer new treatment options for patients with melanoma, cervical cancer, and other types of cancers. Its therapies are developed using advanced cell therapy technologies to address cancers that are resistant to traditional treatments. The company is headquartered in San Carlos, California, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage